Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer

Campos, Susana M.

doi:10.1634/theoncologist.8-suppl_2-10

Cited by 23 publications

(17 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Chemotherapy is used in breast cancer treatment as neoadjuvant, adjuvant or as a primary therapy for metastatic and relapsed breast cancer [1,2]. Acquired resistance to chemotherapy is a major obstacle to successful breast cancer treatment.…”

Section: Introductionmentioning

confidence: 99%

Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells

Saleh

El‐Awady

Alim

et al. 2009

Cell Biochem Biophys

View full text Add to dashboard Cite

This study was designed to investigate the molecular changes that may develop during exposure of breast cancer cells to anticancer agents and that may lead to acquired resistance. We used two breast cancer cell lines, a parental (MCF7/WT) and a doxorubicin-resistant (MCF7/DOX) one. Cell survival, cell cycle distribution and RT-PCR expression level of genes involved in DNA damage response, MDR1, GST and TOPOIIalpha were measured. MCF7/DOX cells were five-fold more resistant to doxorubicin (DOX) than the MCF7/WT cells. DOX treatment causes arrest of MCF7/DOX cells in G1 and G2 phases of cell cycle whereas MCF7/WT cells were arrested in S-phase. The molecular changes in both cell lines due to DOX treatment could be classified into: (1) the basal level of p53, p21, BRCA1, GST and TOPOIIalpha mRNA was higher in MCF7/DOX than MCF7/WT. During DOX treatment, the expression level of these genes decreased in both cell lines but the rate of down-regulation was faster in MCF7/WT than MCF7/DOX cells. (2) The expression level of MDR1 was the same in both cell lines but 48 and 72 h of drug treatment, MDR1 disappeared in MCF7/WT but still expressed in MCF7/DOX. (3) There was no change in the expression level of BAX, FAS and BRCA2 in both cell lines. Conclusively, after validation in clinical samples, overexpression of genes like BRCA1, p53, p21, GST, MDR1 and TOPOIIalpha could be used as a prognostic biomarker for detection of acquired resistance in breast cancer and as therapeutic targets for the improvement of breast cancer treatment strategies.

show abstract

Section: Introductionmentioning

confidence: 99%

Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells

Saleh

El‐Awady

Alim

et al. 2009

Cell Biochem Biophys

View full text Add to dashboard Cite

show abstract

“…Patients received liposomal doxorubicin, 60 mg/m 2 , every 3 weeks and trastuzumab, 4 mg/kg, then 2 mg/kg weekly. That study is discussed in detail elsewhere in this supplement [12]; however, the results are relevant to the current discussion. There were two reports of cardiac toxicity in the small number of patients enrolled, and the overall response rate was 59% (one complete response, 18 partial responses).…”

Section: Liposomal Doxorubicin (D-99)mentioning

confidence: 98%

Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer

Wolff

2003

The Oncologist

View full text Add to dashboard Cite

Breast cancer research is entering a new and promising phase, with greater focus on patient quality of life and therapy selection based on specific targets of interest. Growth factor pathway modulators represent an area of increasing interest for clinicians treating various cancer types, including breast cancer. Therapeutic strategies combining cytotoxic drugs with specific targets using small molecules and targeted antibody therapy may help circumvent potential growth factor survival mechanisms in solid tumors. One of the challenges when combining these agents, however, is the potential for pharmacodynamic and pharmacokinetic BuntingBlaustein Cancer Research Building, 1650 Orleans Street, Room 189, Baltimore, Maryland 21231-1000 Fax: 410-955-0125; e-mail: awolff@jhmi.edu Received July 7, 2003; accepted for publication August 12, 2003. ©AlphaMed Press 1083-7159/2003 INTRODUCTIONBreast cancer research is increasingly focused on mechanistically based therapies and the preservation and improvement of the quality of life of those affected by this disease.

show abstract

“…The specific and preferential targeting and locating of cancer sites by the administration of nanoparticles has greatly evolved as an attractive treatment strategy with a greater therapeutic index, topping the conventional formulations and designs of the same agents [87][88][89][90][91]. The first designed nanodrugs which were approved in the mid-Nineties were doxorubicin [92,93] and liposomal encapsulated antifungals [94]. Another design employed the conjugation of albumin nanoparticles to Cremaphor®-free taxanes, and secured FDA approval in 2005 for the treatment of Breast cancer [95,96].…”

Section: Nanomedicine Stem Cells Cancer Immune Activation Managemementioning

confidence: 99%

Therapeutic nanomedicine surmounts the limitations of pharmacotherapy

Odiba

Ottah

et al. 2017

Open Medicine

View full text Add to dashboard Cite

AbstractScience always strives to find an improved way of doing things and nanoscience is one such approach. Nanomaterials are suitable for pharmaceutical applications mostly because of their size which facilitates absorption, distribution, metabolism and excretion of the nanoparticles. Whether labile or insoluble nanoparticles, their cytotoxic effect on malignant cells has moved the use of nanomedicine into focus. Since nanomedicine can be described as the science and technology of diagnosing, treating and preventing diseases towards ultimately improving human health, a lot of nanotechnology options have received approval by various regulatory agencies. Nanodrugs also have been discovered to be more precise in targeting the desired site, hence maximizing the therapeutic effects, while minimizing side-effects on the rest of the body. This unique property and more has made nanomedicine popular in therapeutic medicine employing nanotechnology in genetic therapy, drug encapsulation, enzyme manipulation and control, tissue engineering, target drug delivery, pharmacogenomics, stem cell and cloning, and even virus-based hybrids. This review highlights nanoproducts that are in development and have gained approval through one clinical trial stage or the other.

show abstract

Liposomal Anthracyclines: Adjuvant and Neoadjuvant Therapy for Breast Cancer

Abstract: ABSTRACT

Cited by 23 publications

References 24 publications

Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells

Altered Expression of Proliferation-Inducing and Proliferation-Inhibiting Genes Might Contribute to Acquired Doxorubicin Resistance in Breast Cancer Cells

Liposomal Anthracyclines and New Treatment Approaches for Breast Cancer

Therapeutic nanomedicine surmounts the limitations of pharmacotherapy

Contact Info

Product

Resources

About